Zhao Jindu, Li Guo-Ying, Lu Xian-Ying, Zhu Li-Ran, Gao Qun
Department of Oncology Surgery, Anhui Medical University Children's Medical Center, Anhui Provincial Children's Hospital, Hefei, Anhui, China.
College of Integrative Medicine, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Front Pharmacol. 2024 Mar 13;15:1376005. doi: 10.3389/fphar.2024.1376005. eCollection 2024.
Liver cancer remains as the third leading cause of cancer-related death globally as of 2020. Despite the significant progress made in the field of liver cancer treatment, there is still a lack of effective therapies in patients with advanced cancer and the molecular mechanisms underlying liver cancer progression remain largely elusive. N6-methyladenosine (mA) modification, as the most prevalent and abundant internal RNA modification in eukaryotic RNAs, plays an essential role in regulating RNA metabolism including RNA splicing, stability, translation, degradation. To date, there is mounting evidence showing that mA dysregulation is closely associated with the onset and development of many tumors including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and hepatoblastoma (HB). In this review, we summarize the last research progress regarding the functions of mA-related regulators in liver cancer and its underlying mechanisms. Additionally, we also discuss the therapeutic applications of mA-based inhibitors in liver cancer treatment.
截至2020年，肝癌仍是全球癌症相关死亡的第三大主要原因。尽管在肝癌治疗领域取得了重大进展，但晚期癌症患者仍缺乏有效的治疗方法，肝癌进展的分子机制在很大程度上仍不清楚。N6-甲基腺苷（m6A）修饰作为真核RNA中最普遍和丰富的内部RNA修饰，在调节RNA代谢（包括RNA剪接、稳定性、翻译、降解）中起着至关重要的作用。迄今为止，越来越多的证据表明，m6A失调与包括肝细胞癌（HCC）、肝内胆管癌（ICC）和肝母细胞瘤（HB）在内的许多肿瘤的发生和发展密切相关。在这篇综述中，我们总结了关于m6A相关调节因子在肝癌中的功能及其潜在机制的最新研究进展。此外，我们还讨论了基于m6A的抑制剂在肝癌治疗中的治疗应用。
